恶性葡萄胎患者血清Hcy和MMP-2、TIMP-2检测的临床评价

目的：评估了恶性葡萄胎患者化疗前后血清Hcy和MMP-2、TIMP-2水平的变化及临床意义。方法：应用酶免法和放射免疫分析对32例恶性葡萄胎患者进行了化疗前后血清Hcy和MMP-2、TIMP检测，并与35名正常妇女作比较。结果：恶性葡萄胎患者在化疗前血清Hcy和MMP-2、TIMP-2水平均非常显著地高于正常妇女组（P〈0．01），化疗后6个月未复发的29例中其水平明显下降或接近正常，而复发的3例，其水平又回升到化疗前水平（P〈0．01）。结论：检测恶性葡萄胎患者血清Hcy和MMP-2、TIMP-2水平的变化可作为患者诊断和疗效观察的参考。

Clinical Evaluation of Determination the Changes on Serum Hcy and MMP-2,TIMP-2 Levels in Patients with Malignant Hydatidiform Mole

Objective To assess the clinical evaluation of serum Hey and MMP-2, TIMP-2 levels both before and after chemotherapy in patients with malignara hydatidiform mole. Methods Semm Hey （with ELISA）, Serum MMP-2, TIMP-2 （with RIA） levels were determined 32 patients with malignant hydatidiform mole and compared with 35 normal parsons served as control. Results Before chemo- therapy serum Hcy and MMP-2,TIMP-2 levels in the patients were significantly higher than those in controls（P 〈0. 01 ） ,6 months after chemotherapy the levels in 29 cases without recurrence remained dropping markedly and approached those in controls. However,in 3 pa- tients with recurrence the levels increased again and approached the former chemotherapy. Conclusion Detection of serum Hcy and MMP-2, IMP-2 levels might be a useful reference for diagnose and therapeutic efficacy in patients with malignant hydalidiform mole.